All In Biotech

Free tool

FAERS Monitor: Midamor

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018200 or its brand name (Midamor, Amiloride Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

858

Serious

731

85% of reports

Hospitalization

398

Death reported

63

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea69
  • diarrhoea58
  • nausea49
  • drug interaction41
  • hyperkalaemia39
  • vomiting39
  • malaise38
  • fatigue37
  • fall36
  • confusional state33
  • headache32
  • abdominal pain29
  • off label use29
  • pruritus29
  • renal failure acute29

Reports by year received

View as table
YearReports
20043
20056
200628
200768
200874
200975
201085
201178
201276
201313
20149
201518
201634
20179
201840
201936
202029
202120
202237
202334
202438
202526
202622

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,301 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyperkalaemiaSignal3927.320.1962
renal failure acuteSignal2916.811.7415
drug interactionSignal416.34.7180
confusional stateSignal335.03.6103
abdominal painSignal293.12.139
dyspnoeaSignal693.02.492
fallSignal362.71.936
diarrhoeaSignal582.21.738
malaiseSignal382.11.622
vomitingSignal392.01.520
pruritus291.81.311
nausea491.51.28
headache321.30.91
fatigue371.20.91
off label use290.80.61

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.